Figure 2.From: Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies Change from baseline in 6MWD in patients with PAH-CHD in PATENT-1 and PATENT-2 Data are observed values (mean±SEM)Data from PATENT-1 are shown for patients who subsequently entered PATENT-26MWD, 6-minute walking distance; SEM, standard error of the meanBack to article page